Orexigen Therapeutics records $31,000 loss from operations for April

By Caroline Salls

Pittsburgh, May 31 – Orexigen Therapeutics, Inc. reported a $31,000 loss from operations for April on zero net product sales, according to its monthly operating report filed with the U.S. Bankruptcy Court for the District of Delaware.

In comparison, Orexigen posted a $708,000 loss from operations for March, also on zero net product sales.

The net gain for April was $3.8 million, improving from a $3.53 million March net loss.

The company had $25.19 million in cash and cash equivalents as of April 30, up slightly from $25.16 million at the end of March.

Orexigen is a San Diego-based biopharmaceutical company focused on the treatment of obesity. The company filed for bankruptcy on March 12, 2018 under Chapter 11 case number 18-10518.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.